SAN DIEGO--(BUSINESS WIRE)--Kurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that the U.S. District Court in Delaware has removed the trial date from the docket in the patent-infringement lawsuit brought against Kurin by Magnolia Medical. The Court indicated that, if necessary, it will provide a trial date after it decides motions for summary judgment. This delay followed Magnolia Medical’s sudden replacement of their lead counsel, Fish & Richardson, with new counsel from the firm Davis Polk.
“As we said more than two years ago when they filed this suit, Magnolia’s case lacks merit and reveals a desperate company with an inferior product that struggles to compete with Kurin in the marketplace,” said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock. “Since filing this lawsuit, they have dropped half of the asserted patents and have now switched law firms, which is never a sign of things going well. While it will likely take years of unnecessary litigation, we will see this through to a successful end.”
“Recently, we have seen Magnolia and its distribution partner offering a dramatic lowering of their price to $14, and we see this as further evidence that these are desperate times for them,” said Dave Lloyd, EVP of Sales and a Co-Founder of Kurin. “We do not know if this is special pricing to find new customers or whether all existing customers are offered this price, but it is another sign that they are struggling in the market.”
“From the beginning, Magnolia Medical has missed the mark with their complicated device,” said Mr. Rogers. “Whether through frivolous lawsuits, lower pricing, or other actions, they keep looking in the wrong place when the answer has always been more basic: clinical outcomes are tied to compliance and compliance is achieved by having a simple solution.”
Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection - simply beyond conventional diversion.
About Kurin, Inc.
Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.